News

Logistics provider announced new hub coming to Kristiansand in February 2024.

Investment offers opportunity to expand global footprint, company says.

DataHorizzon Research anticipates an 18.1% CAGR through next decade.

Thousands of pharmacies will earn streamlined access to the OneScan Pharmacy Pro Platform, company says.

Executive comes with over 20 years of experience in the industry.

Partnership intends to indirectly boost patient medication adherence rates in the process.

Sector is anticipated to grow at a CAGR of 9.3%.

Provider acquires Healthware Group, extending its international footprint.

Northern Ireland hub undergoes $85 million expansion.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.

These components take the burden off drug manufacturers to prep packaging components for sterilization, while helping to enhance the drug filling and packaging process.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

Deal includes Krazati, a therapy for patients with non-small cell lung cancer.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

CDMO’s Heidelberg facility will house the newly-completed manufacturing line.

Acquisition helps expand pharma marketing reach and opens door for growth opportunities.

Packaging manufacturers partner up in effort to help tackle pharma’s demand for recyclable packaging.

Site aims to advance regenerative medicines on a global scale.

The conference will focus on the full breadth of commercialization strategies and operations.

Acquisition includes company’s inflammatory disease medicines.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Exec joins the organization with decades of biopharma experience.